SCHEMBL5654040

SCHEMBL5654040

CC(N)c1cccc(-c2cnccn2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM2 Q9P1W9 2/20 0.45
BACE1 P56817 3/20 0.42
BACE2 Q9Y5Z0 2/20 0.41
DHFR P00374 1/20 0.41
PIK3CD O00329 1/20 0.40
PIK3CA P42336 1/20 0.40
PIK3CB P42338 1/20 0.40
PI4KA P42356 1/20 0.40
PIK3CG P48736 1/20 0.40
PI4KB Q9UBF8 1/20 0.40
CTSD P07339 1/20 0.38
PIM1 P11309 2/20 0.38
CDK8 P49336 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP19A1 P11511 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
ABL1 P00519 1/20 0.38
CIT O14578 1/20 0.38
CYP2A6 P11509 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5888632 1.00 PIM2 (0.45) PIM2BACE1BACE2DHFRPIK3CD
SCHEMBL4024230 0.87 PIM2 (0.47) PIM2BACE1BACE2DHFRPIK3CD
SCHEMBL28799914 0.84 PIM2 (0.45) PIM2BACE1BACE2DHFRPIK3CD
SCHEMBL30018047 0.84 PIM2 (0.47) PIM2BACE1BACE2DHFRPIK3CD
SCHEMBL29793885 0.81 CTSL (0.48) BACE1PIK3CDPIK3CAPI4KAPIK3CG
SCHEMBL5216832 0.81 CTSL (0.48) BACE1PIK3CDPIK3CAPI4KAPIK3CG
SCHEMBL5249260 0.81 CTSL (0.48) BACE1PIK3CDPIK3CAPI4KAPIK3CG
SCHEMBL5218298 0.79 MKNK1 (0.56) BACE1CYP19A1CYP2A6
SCHEMBL5848606 0.79 MKNK1 (0.56) BACE1CYP19A1CYP2A6
SCHEMBL21290740 0.77 PIM2 (0.55) PIM2BACE1BACE2DHFRPIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7091202-B2 4-arylspirocycloalkyl-2-aminopyrimidine carboxamide KCNQ potassium channel modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2006-08-15 US disclosed
US-20060063790-A1 4-Arylspirocycloalkyl-2-aminopyrimidine carboxamide KCNQ potassium channel modulators BRISTOL-MYERS SQUIBB COMPANY 2006-03-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060063790-A1 4-Arylspirocycloalkyl-2-aminopyrimidine carboxamide KCNQ potassium channel modulators KCNQ2, KCNQ1, KCNQ4 PIM2 1511/4885BACE1 588/4885BACE2 527/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.